

Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/M610FFC04EE8EN.html>

Date: December 2019

Pages: 79

Price: US\$ 3,500.00 (Single User License)

ID: M610FFC04EE8EN

Abstracts

Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019

SUMMARY

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Mitogen-activated protein kinase 14 also called p38-alpha is an enzyme belongs to p38 MAPK family. p38-alpha MAPK play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. p38-alpha MAPK is expressed in many cell types. p38-alpha MAPK is implicated in cell apoptosis, proliferation, differentiation, migration, mRNA stability, and inflammatory response in different cell types through variety of different target molecules.

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Immunology, Musculoskeletal Disorders, Respiratory and Undisclosed which include indications Alzheimer's Disease, Pancreatic Cancer, Acute Ischemic

Stroke, Acute Lung Injury, Cognitive Disorders, Dilated Cardiomyopathy, Epithelial Ovarian Cancer, Facioscapulohumeral Muscular Dystrophy (FSHD), Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Ischemic Stroke, Lewy Body Dementia, Melanoma, Multiple Sclerosis, Neuropathic Pain (Neuralgia), Pain, Peritoneal Cancer, Pervasive Developmental Disorder (PDD), Post-Operative Pain, Renal Cell Carcinoma, Rheumatoid Arthritis, Solid Tumor, Ulcerative Colitis and Unspecified.

The latest report Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019, outlays comprehensive information on the Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)

The report reviews Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics and enlists all their major and minor projects

The report assesses Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mitogen

Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Overview

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Companies Involved in Therapeutics Development

EIP Pharma LLC

Eli Lilly and Co

Fulcrum Therapeutics Inc

GEn1E Lifesciences Inc

Ionis Pharmaceuticals Inc

Neurokin Therapeutics

Pfizer Inc

Strekin AG

Synovo GmbH

TopiVert Ltd

Zocere Inc

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Drug Profiles

Antisense Oligonucleotides to Inhibit MAPK14 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iosmapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MW-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neflamapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pamapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MAPK14 and MAPK11 for Multiple Sclerosis, Pancreatic Cancer

Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexmetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06802861 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ralimetinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit MAPK14 for Ischemic Stroke - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Mitogen Activated Protein Kinase 14 for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MAPK14 for Acute Lung Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYD-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOP-1210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Dormant Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Discontinued Products

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Product Development Milestones

Featured News & Press Releases

Dec 05, 2019: EIP Pharma announces presentation of phase 2b clinical trial results of neflamapimod in early-stage alzheimer's disease at clinical trials in alzheimer's disease (CTAD) meeting

Nov 08, 2019: EIP Pharma reports mixed results from neflamapimod Alzheimer's trial

Nov 07, 2019: EIP Pharma announces U.S. FDA grants Fast-Track Designation to Neflamapimod as a treatment for Dementia with Lewy Bodies (DLB)

Oct 31, 2019: Fulcrum Therapeutics to host key opinion leader breakfast symposium on Facioscapulohumeral Dystrophy

Oct 04, 2019: Fulcrum Therapeutics announced results of phase 1 clinical trial of Losmapimod in FSHD

Oct 01, 2019: Fulcrum Therapeutics announces multiple presentations of Losmapimod Data at World Muscle Society Meeting

Sep 04, 2019: Fulcrum Therapeutics appoints Pamela Strode, Seasoned Industry Executive, to lead regulatory affairs team

Aug 21, 2019: Fulcrum launches Phase IIb trial of losmapimod to treat FSHD

Aug 19, 2019: Fulcrum Therapeutics announces initiation of ReDUX4, a phase 2b clinical trial of Losmapimod for FSHD

Jul 17, 2019: EIP Pharma announces presentation of preclinical data demonstrating effects of p38a Kinase Inhibitor Neflamapimod on the neurodegenerative process

Jul 12, 2019: EIP Pharma initiates new study with Neflamapimod for the treatment of cognitive deficits in patients with dementia with lewy bodies

Jul 10, 2019: EIP Pharma trials neflamapimod to treat cognitive deficits

Jul 08, 2019: EIP Pharma appoints Noel Donnelly as CFO

May 15, 2019: Eli Lilly presents update on phase Ib/II study of ralimetinib at ASCO 2019

Dec 13, 2018: EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by EIP Pharma LLC, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Fulcrum Therapeutics Inc, H2 2019
Pipeline by GEn1E Lifesciences Inc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Neurokine Therapeutics, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Strekin AG, H2 2019
Pipeline by Synovo GmbH, H2 2019
Pipeline by TopiVert Ltd, H2 2019
Pipeline by Zocere Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

EIP Pharma LLC

Eli Lilly and Co

Fulcrum Therapeutics Inc

GEn1E Lifesciences Inc

Ionis Pharmaceuticals Inc

Neurokine Therapeutics

Pfizer Inc

Strekin AG

Synovo GmbH

TopiVert Ltd

Zocere Inc

I would like to order

Product name: Mitogen Activated Protein Kinase 14 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/M610FFC04EE8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M610FFC04EE8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970